Transjugular Insertion of Biliary Stents (TIBS) in Two Patients with Malignant Obstruction, Ascites, and Coagulopathy

Amygdalos, Michael A.; Haskal, Ziv J.; Cope, Constantin; Kadish, Steven L.; Long, William B.

doi:10.1007/s002709900024

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rare cases of ascites, a transjugular approach was preferred. The procedure is similar to the transjugular intrahepatic systemic shunt procedure, but, instead of the portal vein, a dilated right bile duct was punctured (14,15).…”

Section: Stent Placement Proceduresmentioning

confidence: 99%

No Advantage of Expanded Polytetrafluoroethylene and Fluorinated Ethylene Propylene–Covered Stents over Uncovered Nitinol Stents for Percutaneous Palliation of Malignant Infrahilar Biliary Obstruction: Results of a Single-Center Prospective Randomized Trial

Dhondt

Vanlangenhove

Man

et al. 2020

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Purpose: To prove that covered stents are more efficacious than uncovered stents regarding patency, safety, enabling of chemotherapy, and survival in percutaneous palliation of malignant infrahilar biliary obstruction.Materials and Methods: After failed endoscopic treatment, 154 patients with obstructive jaundice caused by unresectable infrahilar malignancy were randomly allocated to receive an expanded polytetrafluoroethylene and fluorinated ethylene propylene-covered or an uncovered nitinol stent. Occlusion rate, patency, and survival were assessed. Safety and clinical success in terms of chemotherapy were compared.Results: Three patients were excluded post hoc. Fifteen patients died within 7 d and were excluded from patency analysis. Occlusion rates were 32% (21 of 66) for covered and 29% (20 of 70) for uncovered stents (P ¼ .7). Estimated median patency durations were 308 d (95% confidence interval [CI], 178-438 d) for covered and 442 d (95% CI, 172-712 d) for uncovered stents (P ¼ .1). Serious adverse events (P ¼ 1.0) and 30-day mortality (P ¼ .5) were equivalent between groups. At hospital discharge, median bilirubin reduction of 8 mg/dL was found in both groups (P < .001). In the covered stent group, 35 patients (48%) received palliative chemotherapy, vs 29 (37%) in the uncovered stent group (P ¼ .2). Estimated median survival times were 96 days (95% CI, 68-124 d) with covered stents and 75 days (95% CI, 42-108 d) with uncovered stents (P ¼ .6). Conclusions:In malignant infrahilar biliary obstruction not amenable to endoscopy, no improvement in patency or survival with percutaneously placed covered stents could be confirmed. Covered and uncovered stent types exhibit similar safety profiles and clinical success rates.Palliative drainage for unresectable malignant biliary obstruction is a well-established intervention for relief of jaundice, prevention of cholangitis, and improvement of patients' quality of life (1). Ultimately, chemotherapy can be initiated to prolong survival. Internal drainage was first achieved with polyethylene plastic stents delivered through From the Departments of Vascular and Interventional Radiology (E.

show abstract

Section: Stent Placement Proceduresmentioning

confidence: 99%